middle.news
InhaleRx Secures $12.6M to Advance Oral Esketamine Therapy for Depression
9:39am on Thursday 4th of December, 2025 AEDT
•
Healthcare
Read Story
InhaleRx Secures $12.6M to Advance Oral Esketamine Therapy for Depression
9:39am on Thursday 4th of December, 2025 AEDT
Key Points
Linlithgow Family Office commits additional $12.6M for SRX-25 development
Total funding facility now approximately $52.3M covering three drug programs
SRX-25 combines Esketamine with CYP450 inhibitor to improve oral bioavailability
Funding structured with options issuance tied to Phase 2 trial milestones
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inhalerx (ASX:IRX)
OPEN ARTICLE